CPG Sec. 651.100 Ethylenediamine Dihydroiodide (EDDI)

Issue Date: June 1, 2019
Issued by: Center for Veterinary Medicine
Topic(s): Investigation & Enforcement, Animal Drugs
Status: Final

CPG Sec. 651.100 Ethylenediamine Dihydroiodide (EDDI)

This guidance document represents the Agency’s current thinking on animal products containing ethylenediamine dihydroiodide (EDDI) or feeds containing unapproved new drugs under the provisions of the Federal Food, Drug, and Cosmetic Act (the FD&C Act).

Download the Guidance Document

webmaster2026-08-05T18:58:05+00:00

ABOUT US

Avance Biosciences is a leading Contract Research Organization (CRO) and Contract Testing Organization (CTO) providing CGMP and GLP-compliant analytical and bioanalytical services to support drug development. From early discovery through clinical development and commercialization, we provide CGMP and GLP-compliant services tailored to your therapeutic modality and regulatory needs.